- Home
- BLRX
BLRX
BioLineRx Ltd.
as 12-18-2024 4:00pm EST
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
| Founded: | 2003 | Country: | Israel |
| Employees: | N/A | City: | N/A |
| Market Cap: | 36.0M | IPO Year: | 2011 |
| Target Price: | $5.50 | AVG Volume (30 days): | 2.2M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.02 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.19 - $1.70 | Next Earning Date: | 11-25-2024 |
| Revenue: | $21,991,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BioLineRx Ltd. News
BLRX Breaking Stock News: Dive into BLRX Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
15 days ago
BLRX: Ayrmid Assumes Commercialization Efforts
GuruFocus.com
22 days ago
BioLine Rx Ltd (BLRX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Shifts
PR Newswire
23 days ago
BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value
TipRanks
a month ago
BioLineRx, Ayrmid enter license agreement for motixafortide through Gamida Cell
PR Newswire
a month ago
BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.
PR Newswire
a month ago
BioLineRx to Report Third Quarter 2024 Results on November 25, 2024
PR Newswire
a month ago
BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024
PR Newswire
2 months ago
BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide
Compare BLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BLRX BioLineRx Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.